MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.
NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan
Related news for (MDWD)
- MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
- MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
- MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care